drugset / Trial / NCT03346187

A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337

NCT03346187

Phase 1 Completed 60 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety and pharmacokinetic characteristics of CKD-337 in healthy male volunteers

Timeline

Start
2017-05-19
Primary completion
2017-05-31
Completion
2017-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-335 Small molecule 178.8 mg Oral
Subject Atorvastatin Small molecule 20 mg Oral
Subject Fenofibrate Small molecule 160 mg Oral
Subject Fenofibrate Small molecule 178.8 mg Oral

Indications